Related Experiment Video
Updated: May 14, 2026

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images
Published on: September 7, 2017
Promoter hypermethylation contributes to TIMP3 down-regulation in high stage endometrioid endometrial carcinomas
Lluis Catasus1, Cristina Pons, Josefina Muñoz
1Department of Pathology, Hospital de la Santa Creu i Sant Pau, Institute of Biomedical Research, Autonomous University of Barcelona, Barcelona, Spain. lcatasus@santpau.cat
Aims:
Expression of tissue inhibitor of metalloproteinases-3 (TIMP-3) has been found to be decreased in several types of cancer by promoter gene hypermethylation. However, little is known regarding the silencing effect of TIMP3 promoter hypermethylation on gene and protein expression in endometrial carcinomas and its prognostic significance.
Methods And Results:
TIMP3 promoter hypermethylation and gene copy number variations were evaluated using a methylation-specific multiplex ligation-dependent probe amplification approach in 60 cases of endometrioid endometrial carcinomas. TIMP3 expression was also evaluated at the transcript and protein levels. Loss of TIMP-3 protein expression was found in 44 (73%) of 60 carcinomas. Promoter hypermethylation was identified in 25% (15 of 60); was more frequent in stages II-IV (55%, six of 11) than in stage I (18%, nine of 49; P = 0.021); and was found more commonly in tumours with deep myometrial invasion. MLH1 and TIMP3 promoters were hypermethylated simultaneously in the same group of tumours (P < 0.001). A correlation between TIMP3 methylation and microsatellite instability (MSI) was found (P = 0.005). TIMP3 copy number changes were frequently a loss (35%), whereas a gain was detected in only 5%.
Conclusions:
TIMP3 promoter hypermethylation was associated with high stage endometrioid endometrial tumours with extrauterine spread. Nevertheless, promoter hypermethylation and loss of heterozygosity are not the only mechanisms for TIMP3 inactivation.
Insights
Tissue inhibitor of metalloproteinases-3 (TIMP-3) promoter hypermethylation is linked to advanced endometrial cancer stages. This epigenetic silencing impacts TIMP-3 expression, potentially affecting tumor progression and prognosis in endometrial carcinomas.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Tissue inhibitor of metalloproteinases-3 (TIMP-3) expression is often reduced in cancers due to promoter hypermethylation.
- The specific role of TIMP3 promoter hypermethylation in endometrial carcinomas and its prognostic implications remain largely unexplored.
Purpose of the Study:
- To investigate the frequency and significance of TIMP3 promoter hypermethylation in endometrioid endometrial carcinomas.
- To evaluate the correlation between TIMP3 hypermethylation, gene/protein expression, and clinicopathological features.
Main Methods:
- Methylation-specific multiplex ligation-dependent probe amplification was used to assess TIMP3 promoter hypermethylation and copy number variations in 60 endometrial carcinoma cases.
- TIMP3 transcript and protein expression levels were analyzed.
Main Results:
- Loss of TIMP-3 protein expression was observed in 73% of tumors.
- TIMP3 promoter hypermethylation occurred in 25% of cases, being more prevalent in advanced stages (II-IV) and tumors with deep myometrial invasion.
- Simultaneous hypermethylation of MLH1 and TIMP3 promoters was noted, along with a correlation between TIMP3 methylation and microsatellite instability (MSI).
Conclusions:
- TIMP3 promoter hypermethylation is associated with high-stage endometrioid endometrial tumors, particularly those with extrauterine spread.
- While hypermethylation contributes to TIMP3 inactivation, other mechanisms like loss of heterozygosity are also involved.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
MicroRNAs
MicroRNAs
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

